Clinical Trial Update: Stereotactic Ablative Radiotherapy With Nivolumab for Early-Stage Operable Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating stereotactic ablative radiotherapy with nivolumab for early-stage operable non-small cell lung cancer (Stage I).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Hospital Israelita Albert Einstein | Conditions: Non-small Cell Lung Cancer Stage I | Phase 2 | Status: COMPLETED